Validation of tissue microarray technology in malignant pleural mesothelioma

Steven Kao; Kenneth Lee; Nicola Armstrong; Stephen Clarke; Janette Vardy; Nico van Zandwijk; Glen Reid; Juliet Burn; Brian McCaughan; Douglas Henderson; Sonja Klebe

doi:10.1097/PAT.0b013e328342016c

Validation of tissue microarray technology in malignant pleural mesothelioma

Steven Kao, Kenneth Lee, Nicola Armstrong, Stephen Clarke, Janette Vardy, Nico van Zandwijk, Glen Reid, Juliet Burn, Brian McCaughan, Douglas Henderson, Sonja Klebe

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Aims: Tissue microarray (TMA) technology has been utilized for assessment of cancers including malignantpleural mesothelioma (MPM). Given the intralesional heterogeneity of MPM, it is questionable if TMAs can adequately represent MPMs. We here investigate the validity of TMAs for MPM. Methods: TMAs were constructed from at least five cores for each of 80 archival tumoursProcessed by two centres between 1994 and 2009. Thepercentage of cases correctly subtyped on TMAs compared with whole sections, in relation to the number of cores analysed, was calculated. Immunohistochemical labelling for calretinin and D2-40 wasperformed on TMAs and whole sections. To evaluate the validity of quantitative immunohistochemistry,percentages ofpositive cells were recorded and two-way analysis of variance (ANOVA)performed. Results: Five cores were assessable for 91% ofpatients. Four cores were sufficient to reach concordance with the whole-section result in 98% of cases for calretinin and 99% for D2-40. The correlation of the quantitative scores between the whole section and TMA cores was statistically significant (D2-40, rho=0.84,p<2.2e-16; calretinin, rho=0.65,p=7.9e-11). Neither the origin nor age of the blocks affected the results. Conclusion: If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.

Original language	English
Pages (from-to)	128-132
Number of pages	5
Journal	Pathology
Volume	43
Issue number	2
DOIs	https://doi.org/10.1097/PAT.0b013e328342016c
Publication status	Published - Feb 2011

Keywords

Calretinin
D2-40
Malignant mesothelioma
Tissue microarray

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/PAT.0b013e328342016c

Cite this

@article{2cc25eaae37343f185bbf950eb8239f8,

title = "Validation of tissue microarray technology in malignant pleural mesothelioma",

abstract = "Aims: Tissue microarray (TMA) technology has been utilized for assessment of cancers including malignantpleural mesothelioma (MPM). Given the intralesional heterogeneity of MPM, it is questionable if TMAs can adequately represent MPMs. We here investigate the validity of TMAs for MPM. Methods: TMAs were constructed from at least five cores for each of 80 archival tumoursProcessed by two centres between 1994 and 2009. Thepercentage of cases correctly subtyped on TMAs compared with whole sections, in relation to the number of cores analysed, was calculated. Immunohistochemical labelling for calretinin and D2-40 wasperformed on TMAs and whole sections. To evaluate the validity of quantitative immunohistochemistry,percentages ofpositive cells were recorded and two-way analysis of variance (ANOVA)performed. Results: Five cores were assessable for 91% ofpatients. Four cores were sufficient to reach concordance with the whole-section result in 98% of cases for calretinin and 99% for D2-40. The correlation of the quantitative scores between the whole section and TMA cores was statistically significant (D2-40, rho=0.84,p<2.2e-16; calretinin, rho=0.65,p=7.9e-11). Neither the origin nor age of the blocks affected the results. Conclusion: If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.",

keywords = "Calretinin, D2-40, Malignant mesothelioma, Tissue microarray",

author = "Steven Kao and Kenneth Lee and Nicola Armstrong and Stephen Clarke and Janette Vardy and {van Zandwijk}, Nico and Glen Reid and Juliet Burn and Brian McCaughan and Douglas Henderson and Sonja Klebe",

year = "2011",

month = feb,

doi = "10.1097/PAT.0b013e328342016c",

language = "English",

volume = "43",

pages = "128--132",

journal = "Pathology",

issn = "0031-3025",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Validation of tissue microarray technology in malignant pleural mesothelioma

AU - Kao, Steven

AU - Lee, Kenneth

AU - Armstrong, Nicola

AU - Clarke, Stephen

AU - Vardy, Janette

AU - van Zandwijk, Nico

AU - Reid, Glen

AU - Burn, Juliet

AU - McCaughan, Brian

AU - Henderson, Douglas

AU - Klebe, Sonja

PY - 2011/2

Y1 - 2011/2

N2 - Aims: Tissue microarray (TMA) technology has been utilized for assessment of cancers including malignantpleural mesothelioma (MPM). Given the intralesional heterogeneity of MPM, it is questionable if TMAs can adequately represent MPMs. We here investigate the validity of TMAs for MPM. Methods: TMAs were constructed from at least five cores for each of 80 archival tumoursProcessed by two centres between 1994 and 2009. Thepercentage of cases correctly subtyped on TMAs compared with whole sections, in relation to the number of cores analysed, was calculated. Immunohistochemical labelling for calretinin and D2-40 wasperformed on TMAs and whole sections. To evaluate the validity of quantitative immunohistochemistry,percentages ofpositive cells were recorded and two-way analysis of variance (ANOVA)performed. Results: Five cores were assessable for 91% ofpatients. Four cores were sufficient to reach concordance with the whole-section result in 98% of cases for calretinin and 99% for D2-40. The correlation of the quantitative scores between the whole section and TMA cores was statistically significant (D2-40, rho=0.84,p<2.2e-16; calretinin, rho=0.65,p=7.9e-11). Neither the origin nor age of the blocks affected the results. Conclusion: If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.

AB - Aims: Tissue microarray (TMA) technology has been utilized for assessment of cancers including malignantpleural mesothelioma (MPM). Given the intralesional heterogeneity of MPM, it is questionable if TMAs can adequately represent MPMs. We here investigate the validity of TMAs for MPM. Methods: TMAs were constructed from at least five cores for each of 80 archival tumoursProcessed by two centres between 1994 and 2009. Thepercentage of cases correctly subtyped on TMAs compared with whole sections, in relation to the number of cores analysed, was calculated. Immunohistochemical labelling for calretinin and D2-40 wasperformed on TMAs and whole sections. To evaluate the validity of quantitative immunohistochemistry,percentages ofpositive cells were recorded and two-way analysis of variance (ANOVA)performed. Results: Five cores were assessable for 91% ofpatients. Four cores were sufficient to reach concordance with the whole-section result in 98% of cases for calretinin and 99% for D2-40. The correlation of the quantitative scores between the whole section and TMA cores was statistically significant (D2-40, rho=0.84,p<2.2e-16; calretinin, rho=0.65,p=7.9e-11). Neither the origin nor age of the blocks affected the results. Conclusion: If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.

KW - Calretinin

KW - D2-40

KW - Malignant mesothelioma

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=79955953946&partnerID=8YFLogxK

U2 - 10.1097/PAT.0b013e328342016c

DO - 10.1097/PAT.0b013e328342016c

M3 - Article

SN - 0031-3025

VL - 43

SP - 128

EP - 132

JO - Pathology

JF - Pathology

IS - 2

ER -

Validation of tissue microarray technology in malignant pleural mesothelioma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this